茚达特罗联合格隆溴铵减轻肺过度充气对COPD患者心室充盈的影响(CLAIM研究)
CLAIM是一项在德国汉诺威单中心开展的双盲、随机、两周期交叉、安慰剂对照研究,纳入62例年龄≥40岁、存在肺过度充气(残气量>135%预计值)的COPD患者。
要点
- LABA-LAMA双支气管扩张剂可显著改善COPD合并肺过度充气患者的左心室舒张末期容积指数。
- 该研究为首个分析LABA-LAMA对COPD患者心脏功能影响的研究。
- 结果支持对存在肺过度充气征象的COPD患者早期使用双支气管扩张治疗。
核心结论
- 茚达特罗-格隆溴铵双支气管扩张治疗可显著改善COPD合并肺过度充气患者的左心室舒张末期容积指数,支持在此类患者中早期使用双支气管扩张治疗。
研究设计与样本
- 双盲、随机、两周期交叉、安慰剂对照、单中心研究(CLAIM),在德国汉诺威Fraunhofer毒理与实验医学研究所开展。
- 随机分配62例患者(1:1)接受茚达特罗110 μg(马来酸盐)联合格隆溴铵50 μg每日一次共14天,或匹配安慰剂,两周期之间洗脱14天。
- 主要终点为按体表面积标化的左心室舒张末期容积(MRI测量),在意向治疗人群(62例)和符合方案人群(60例)中分析。
- 研究注册号NCT02442206,2015年5月18日至2017年4月20日随机分配患者。
主要发现
- 茚达特罗-格隆溴铵组最常见不良事件为咳嗽(9例,15%)和咽部刺激(7例,12%);安慰剂组为头痛(5例,8%)和上呼吸道感染(4例,7%)。
- 严重不良事件2例:茚达特罗-格隆溴铵组1例(子宫内膜癌,2%),安慰剂组1例(心肌梗死,2%),均认为与治疗无关;无患者死亡。
关键数值与推荐
- 肺过度充气定义为基线残气量>135%预计值。
临床怎么用
- 对存在肺过度充气征象的COPD患者,可考虑早期使用茚达特罗-格隆溴铵双支气管扩张治疗以改善心脏功能。
- 治疗决策需结合患者心血管合并症情况,排除心律失常、心力衰竭、不稳定缺血性心脏病或未控制高血压者。
局限性
- 单中心研究,样本量较小(随机62例,符合方案60例)。
- 交叉设计、随访14天,长期心脏功能获益未评估。
- 研究由Novartis Pharma GmbH资助。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pulmonary hyperinflation in chronic obstructive pulmonary disease (COPD) is associated with reduced biventricular end-diastolic volumes and increased morbidity and mortality. The combination of a long-acting β agonist (LABA) and a muscarinic antagonist (LAMA) is more effective in reducing hyperinflation than LABA-inhaled corticosteroid combination therapy but whether dual bronchodilation improves cardiac function is unknown. METHODS: We did a double-blind, randomised, two-period crossover, placebo-controlled, single-centre study (CLAIM) at the Fraunhofer Institute of Toxicology and Experimental Medicine (Hannover, Germany), a specialty clinic. Eligible participants were patients aged at least 40 years with COPD, pulmonary hyperinflation (defined by a baseline residual volume >135% of predicted), a smoking history of at least ten pack-years, and airflow limitation (FEV1 <80% predicted and post-bronchodilator FEV1: forced vital capacity <0·7). Patients with stable cardiovascular disease were eligible, but those with arrhythmias, heart failure, unstable ischaemic heart disease, or uncontrolled hypertension were not. We randomly assigned participants (1:1) to either receive a combined inhaled dual bronchodilator containing the LABA indacaterol (110 μg as maleate salt) plus the LAMA glycopyrronium (50 μg as bromide salt) once per day for 14 days, followed by a 14-day washout, then a matched placebo for 14 days, or to receive the same treatments in reverse order. The randomisation was done using lists and was concealed from patients and investigators. The primary endpoint was the effect of indacaterol-glycopyrronium versus placebo on left-ventricular end-diastolic volume measured by MRI done on day 1 (visit 4) and day 15 (visit 5) in treatment period 1 and on day 29 (visit 6) and day 43 (visit 7) in treatment period 2 in the per-protocol population. Left-ventricular end-diastolic volume was indexed to body surface area. Safety was assessed in all participants who received at least one dose of the study drug. This study is registered with ClinicalTrials.gov, number NCT02442206. FINDINGS: Between May 18, 2015, and April 20, 2017, we randomly assigned 62 eligible participants to treatment; 30 to indacaterol-glycopyrronium followed by placebo and 32 to placebo followed by indacaterol-glycopyrronium. The 62 randomly assigned patients were included in the intent-to-treat analysis. There were two protocol violations and therefore 60 were included in the per-protocol analysis. 57 patients completed both treatment periods. After indacaterol-glycopyrronium treatment, left-ventricular end-diastolic volume increased from a mean 55·46 mL/m2 (SD 15·89) at baseline to a least-squares (LS) mean of 61·76 mL/m2 (95% CI 57·68-65·84), compared with a change from 56·42 mL/m2 at baseline (13·54) to 56·53 mL/m2 (52·43-60·62) after placebo (LS means treatment difference 5·23 mL/m2 [95% CI 3·22 to 7·25; p<0·0001]). The most common adverse events reported with indacaterol-glycopyrronium were cough (in nine patients [15%] of 59) and throat irritation (in seven [12%]). With placebo, the most common adverse events reported were headache (in five patients [8%] of 61) and upper respiratory tract infection (in four [7%]). Two patients had serious adverse events: one (2%) after indacaterol-glycopyrronium (endometrial cancer) and one (2%) after placebo (myocardial infarction); these were not thought to be treatment related. No patients died during the study. INTERPRETATION: This is the first study to analyse the effect of LABA-LAMA combination therapy on cardiac function in patients with COPD and lung hyperinflation. Dual bronchodilation with indacaterol-glycopyrronium significantly improved cardiac function as measured by left-ventricular end-diastolic volume. The results are important because of the known association of cardiovascular impairment with COPD, and support the early use of dual bronchodilation in patients with COPD who show signs of pulmonary hyperinflation. FUNDING: Novartis Pharma GmbH.
引用
- Hohlfeld JM, Vogel-Claussen J, Biller H, et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir Med. 2018. PMID: 29477448. doi:10.1016/S2213-2600(18)30054-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。